In this issue:
Host genetic factors in HEV infection
IRAK2 and its genetic variants hamper spontaneous HCV clearance
Sofosbuvir + daclatasvir treats FCH post-liver transplant
HepaRG cells: use to study innate immune responses
Low vitamin D levels prevalent in untreated HBV infection
Statins lower risk of HCC in chronic HBV infection
. . . and inhibit cirrhosis progression in HCV infection
Nucleos(t)ide analogues suppress oesophageal varices
Emerging combination treatment options for HCV subgroups
Bradycardia after amiodarone + sofosbuvir + DAA
Please login below to download this issue (PDF)